SEC Form 4 · accession 0000899243-17-006711
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen J Tulipano
Officer — Chief Financial Officer
Period of report
Mar 3, 2017
Accepted (ET)
Mar 7, 2017 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $5.10 | Mar 3, 2017 | A | 220,980 | A | — | Mar 2, 2027 | Common Stock | 220,980 | 220,980 | D |
Explanation of responses
- F1The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2017.